The mammalian neostriatum plays a critical role in motor and cognitive functions. A major source of excitatory innervation of the neostriatum is the projection from the cerebral cortex which utilizes the excitatory amino acid glutamate as a transmitter (McGeer et al., 1977; Fonnum et al., 1981) . There are two general forms of glutamate receptors (GluRs): (1) ionotropic GluRs which are ligand-gated cation channels; and (2) metabotropic GluRs which are coupled to various signal transduction processes through GTP binding proteins (Monaghan et al., 1989; Hollmann and Heinemann, 1994) . The ionotropic GluRs can be further classified into three broad subtypes as N-methyl-D-as-partate (NMDA), amino-3-hydroxy-5-methyl-4-isoazole propionic acid (AMPA), and kainate (KA) receptors. A variety of evidence indicates that each of these receptor subtypes are present within the neostriatum.
For example, electrical stimulation of cortical inputs evokes excitatory postsynaptic potentials (EPSPs) in neostriatal neurons which are largely mediated by the AMPAIKA GluRs, although NMDA GluRs can also play a role (Herrling, 1985; Cherubini et al., 1988; Calabresi et al., 1990) . Dysfunctions in these excitatory synapses have been suggested to play a role in the pathology of such diverse neurological disorders as Huntington's disease (DiFiglia, 1990 ) and obsessive-compulsive disorder (Baxter et al., 1992) . Thus, understanding the mechanisms involved in the regulation and modulation of this synaptic connection may prove to be clinically important.
Recently, there have been reports that the adenylate cyclase cascade regulates glutaminergic synaptic transmission (e.g., Cerne et al., 1992; Chavez-Noriega and Stevens, 1992) , and this regulation may be important in the neostriatum. First, both forskolin binding sites (Gehlert et al., 1985; Worley et al., 1986; Poat et al., 1988) and adenylate cyclase mRNA (Matsuoka et al., 1992; Glatt and Snyder, 1993) are abundant in this region. Second, ample evidence from biochemical studies indicates that forskolinand receptor-mediated regulation of adenylate cyclase occurs in the neostriatum (e.g., Stoof and Kebabian, 198 1; Daly et al., 1982; Battaglia et al., 1986; Matsuoka et al., 1992; Prezeau et al., 1992) . Finally, dopamine and metabotropic GluRs have been shown to both regulate adenylate cyclase activity and modulate ionotropic GluR agonist-induced responses in this region (Cepeda et al., 1993; Colwell and Levine, 1994) . Consequently, the purpose of the present study was to directly investigate whether CAMP-dependent regulation of both excitatory synaptic transmission and GluRs occurs in the neostriatum. Experiments were designed to determine (1) the effects of forskolin on EPSPs recorded in neostriatal neurons, (2) whether these effects are mediated by CAMP-dependent protein kinase, (3) the role of tonic kinase and phosphatase activity in regulating the EPSP, (4) the effects of forskolin on membrane properties of neostriatal neurons, and (5) the effects of forskolin on NMDA and AMPA/KA GluR-induced responses in these neurons.
Materials and Methods
Preparation of neostriatal slices. Adult male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) were maintained in small groups with continuous access to food and water. After animals were killed by decapitation, brains were dissected and placed in cold oxygenated artificial cerebrospinal fluid (ACSF) containing (in mM) NaCl 124, NaHCO, 26, KCL 5, MgSO, 2, NaH,PO, 1.25, CaC& 2.4, and glucose 10 (pH 7.2-7.4). Transverse sections (400 pm) were cut and incubated in ACSF at 35-37°C for l-2 hr. Tissue was then transferred to the recording chamber at least 30 min prior to recording. The slice rested upon filter paper in the "interface-type" recording chamber and was superfused continuously by oxygenated ACSF (35-37°C). A warm, humidified gas (95% O,, 5% CO,) flowed over the top surface of the slice. Intracellular recording. Intracellular recordings were obtained with glass microelectrodes filled with 3 M potassium acetate. DC resistances varied from 70-100 MR The signal was amplified by an active bridge circuit (Axoclamp 2A amplifier, Axon Instruments, Foster City, CA) and stored on videotape for later analysis. After a neuron was impaled, a baseline recording was obtained to ensure that the cell's membrane properties were stable. Baseline membrane potential was maintained throughout the course of the experiment by manually adjusting the DC current. This injected current was never more than LO.5 nA and typically was not needed until >90 min into the recording. Most data were collected without DC current injection. Hyperpolarizing current pulses (0.2-0.4 nA, 50 msec duration, 0.5 per set) were applied throughout all experiments to measure conductance changes. In some neurons, the current-voltage relationship was obtained by injection of depolarizing and hyperpolarizing pulses (100 msec duration); the cell's input resistance was determined from the linear portion of the current-voltage plots. Membrane excitability was measured as the response of the neuron to depolarizing current pulses (0.1 nA steps, 500 msec duration). Not all measurements were obtained for each cell. Most recordings were made from cells in the dorsomedial region of the neostriatum.
Electrophysiological information on the effects of experimental treatments on action potential (AP) and afterhyperpolarization (AHP) duration and amplitude was obtained by analyzing the first AP evoked by the current pulses. The AP amplitudes were measured from the start of the rising phase to the peak of depolarization, while durations were measured at half amplitude. The rise times were measured as the time from the start of the AP to the peak, while the fall times were measured from the peak to the membrane's return to baseline potential. The amplitudes of the AHPs were measured from start of the AP to the maximal deflection of the hyperpolarization, while durations were determined as the time from the start of the hyperpolarization until the membrane potential returned to its baseline value.
In some cases, the recording electrodes were filled with a 2% solution of biocytin dissolved in 3 M potassium acetate. After completion of the experiment, these slices were fixed in paraformaldehyde and then processed by standard techniques to identify recorded cells (Horikawa and Armstrong, 1988) .
Electrical stimulation. The stimulating electrode used to evoke EPSPs consisted of a pair of 0.2 mm insulated stainless steel wires separated by a 0.5 mm shaft (David Kopf Instruments, Tujunga, CA). Contacts were exposed by 0.5 mm. It was placed approximately l-3 mm from the recording electrode. To activate the corticostriatal fibers, one tip was placed in the corpus callosum while the other was placed in the dorsal neostriatum. Stimuli consisted of 100 p.sec square wave pulses of varying amplitudes. Electrical stimulation evoked an EPSP which was blocked by GluR antagonists, low calcium solutions, or tetrodotoxin. The EPSP amplitudes were measured from the start of the rising phase to the peak depolarization, while durations were measured at half amplitude. Under control conditions, the EPSP amplitude was stable over the l-2 hr in which these experiments were typically performed.
lontophoresis. For iontophoresis, a five-barrelled pipette was placed close (100-200 pm) to the recording electrode. Iontophoretic and recording electrodes were held by separate electrode carriers. This configuration minimized electrical interactions between recording and microphoretic electrodes. Each barrel contained one of the following solutions: AMPA (20 mM, pH 8, Research Biochemical, Natick, MA), glutamate (100 mM, pH 8.5, Sigma, St. Louis, MO), quisqualate (100 mM, pH 8, Tocris Neuramin, Bristol, UK), NMDA (100 mM, pH 8, Sigma), and saline for current balancing and controls. Not all drugs were used in each experiment. All drugs were iontophoretically ejected as anions and were prevented from diffusing out of the barrel by a positive holding current of 15-20 nA. In some experiments, current balancing was carried out through a barrel containing 1 M NaCl. No differences were observed between experiments with or without current balancing.
To study the effects of iontophoretically applied excitatory amino acid agonists, ejection currents were adjusted to induce reproducible submaximal responses. Ejection times ranged from 2-8 sec. The interval between ejection pulses varied from 2-3 min. Iontophoretic currents used to induce these responses ranged from 10 to 200 nA. Controls consisted of the application of negative currents of equal magnitude and duration through the saline-containing barrel of the pipette. In no case did the application of saline either cause membrane potential changes by itself (>l mV) or alter a cell's response to an EAA agonist. Perhaps due to the fact that the iontophoretic and recording electrodes are held by separate electrode manipulators, current artifacts as a result of iontophoretic stimulation are not commonly seen.
Drugs. Pharmacological agents applied in the bath included 2-amino-3-phosphonopentanoic acid @I-3), 2-amino-5-phosphonopentanoic acid (AP-5), bicuculline, 6-cyano-7-nitroquinozaline-2,3-dione (CNQX), forskolin and 1,9-dideoxyforskolin, okadaic acid and I-nor-okadaone (Calbiochem, La Jolla, CA), Rp-and Sp-CAMPS, and tetrodotoxin (TTX, Sigma). Unless otherwise noted, drugs were purchased from Research Biochemicals.
Forskolin and 1,9-dideoxyforskolin were mixed as a stock solution in dimethylsulfoxide (DMSO) and diluted to final concentration in ACSE The final DMSO concentration was never higher that 0.25%. In previous control experiments, this concentration of DMSO did not alter the synaptic-evoked response. Both forskolin and 1,9-dideoxyforskolin contained the same concentration of DMSO. Other bath-applied drugs were directly dissolved in ACSE The protein kinase A inhibitor IP,,-amide (PKI, 0.5 mM) was dissolved in potassium acetate and applied intracellularly by allowing it to leak from the recording electrode.
Statistical analysis. Differences between average values for experimental and control groups were evaluated using paired t tests. The ability of PKA antagonists to inhibit forskolin's actions was evaluated using a one-way ANOVA followed by Tukey's multiple comparison procedure. Values were considered significantly different if p < 0.05. In the text, values are shown as means + SEM.
Results
A total of 86 neurons in the rat neostriatum were studied. Neostriatal neurons exhibited an average resting potential of -80.4 + 1.1 mV and an input resistance of 25.2 + 3.9 Mfl, As many as 95% of the neurons in the neostriatum are projection neurons referred to as medium spiny neurons (Gerfen, 1992) and it is likely that most, if not all, of the data in the present study were collected from this cell type. In all cases examined (5/5), the neostriatal cells identified by intracellular injection of biocytin exhibited the morphological characteristics of medium spiny neurons.
Forskolin reversibly enhances EPSPs recorded from neostriatal neurons
Electrical stimulation of corticostriatal fibers evoked an EPSP in all cells tested (n = 61). The average peak depolarization was 13.1 2 0.6 mV (range 4-37 mV). The average duration at half maximal amplitude was 11.1 + 0.8 msec (range 9-16 msec). Bath application of forskolin (10 FM, 5-10 min) enhanced the EPSP amplitude (156 ? 2% of pretreatment controls, n = 17, p < 0.00001) and duration (122 ? 6%, p < 0.01, Fig. 1 ). In 10117 cases, the EPSP amplitude showed a short (5-10 min) depression prior to enhancement. However, this effect was not significant and was not further explored. The enhancement peaked 25 2 3 min (n = 15) after the end of the forskolin treatment and was reversible in most cases (average recovery time 57 + 4 min, range 40-80 min, n = 13, Fig. 2C ). The magnitude of this potentiation increased after exposure to increasing concentrations of forskolin (Fig. 1B) .
Forskolin has been reported to act directly on ion channels without action on the CAMP cascade (e.g., Laurenza et al., 1989) . To test this possibility, the forskolin analog 1 $dideoxyforskolin (10 FM) was applied. This compound, which does not stimulate adenylate cyclase but mimics other actions of forskolin, did not have any consistent action on EPSP amplitude ( Fig.  1B ; 94 * 4% of controls, IZ = 4).
One mechanism by which forskolin could enhance the EPSP is through a decrease in GABA,-mediated inhibition (e.g., Heuschneider and Schwartz, 1989; Porter et al., 1990) . However, bath application of the GABA, receptor antagonist bicuculline does not alter the amplitude of EPSPs evoked by stimulation of corticostriatal fibers (Jiang and North, 1991) . Furthermore, forskolin-induced enhancement of the EPSP was unaltered by the presence of bicuculline ( Fig. 1B ; peak EPSP amplitude 159 + 20% of controls, n = 4). Thus, regulation of a GABA,-mediated process is unlikely to be responsible for forskolin's enhancement of excitatory synaptic transmission. was applied 10 min before and continued 10 min after forskolin (10 PM) treatment, the EPSP amplitude was not significantly altered (average peak 111 -t 6% of pretreatment controls, n = 7). Furthermore, bath application of the PKA activator Sp-CAMPS (Van Haaster et al., 1984 ; 100 pM, 10 min) produced an enhancement of EPSP amplitude in five out of six cases (Fig.  2B , peak amplitude 131 ? 12% of controls, n = 6, p < 0.05).
Inhibition of kinase and phosphatase activities can also alter the evoked EPSP Treatment with the PKA inhibitor Rp-CAMPS (100 PM, 5-10 min) alone decreased the average EPSP amplitude (92 ? 3% of controls, n = 11, p < 0.05). In order to further explore this inhibitory action, the intracellularly active PKA inhibitor PKI (Cheng et al., 1986 ) was added to the recording electrode (0.5 IIIM) and allowed to diffuse into the cell. While untreated controls typically maintain a stable EPSP amplitude (102 + 4%, n = 1 I), treatment with PKI produced a consistent decrease in the EPSP amplitude. After 30 min, EPSP amplitude declined to 67 ? 7% of initial values (n = 7, p < 0.005). At this point, the application of forskolin (10 pM) reversed the inhibition caused by PKI and returned the EPSP amplitude to control levels (106 + 11% of controls, n = 7). Although this effect of forskolin was not significantly different from pretreatment controls, the increase was significant compared to the group treated with PKI alone (p < 0.05). These findings suggest that tonic PKA activity may regulate the synaptic-evoked response. In order to examine the possible role of phosphatase activity, the protein phosphatase inhibitor okadaic acid (Cohen et al., 1990) was applied. This treatment (10 pM, 10 min) increased the EPSP amplitude ( Fig.  2B ; 147 + 13%, n = 5, p < 0.05). In contrast, lower doses of okadaic acid (0.5-1.0 FM, n = 3) or the analog 1-nor-okadaone (n = 2), which lacks phosphatase inhibitory activity, did not alter the evoked EPSF! At the 10 p,M concentration effective in the present study, okadaic acid acts as a nonselective inhibitor of protein phosphatases 1, 2A, and 2B (Bjalojan and Takai, 1988; Cohen et al., 1989 ).
Forskolin's effect on intrinsic membrane properties of neostriatal neurons does not explain the potentiation of the EPSP In order to develop a better understanding of the ionic mechanisms responsible for the enhancement of the EPSP, the effects of forskolin on membrane properties of neostriatal neurons were examined. Bath application with forskolin did not significantly alter any of the parameters measured (Table 1) . However, among individual neurons, reversible changes in membrane potential and input resistance were observed. Thus, possible effects of CAMP on the membrane properties of neostriatal cells do not adequately explain the consistent enhancement of the synapticevoked responses caused by forskolin.
Forskolin enhanced the responsiveness of neostriatal neurons to GluR agonists One mechanism by which forskolin could potentiate synaptic transmission is by enhancing the postsynaptic response of neostriatal neurons to GluR activation. Under the conditions in which the present experiments were performed, the iontophoretic application of GluR agonists including glutamate, quisqualate, and AMPA induced depolarizing responses mediated by AMPAIKA GluRs; that is, these responses were blocked by the antagonist CNQX but not by AP-5 or AP-3. These agonists induced an average peak depolarization of 8.5 f. 1 mV (range 2-18 mV, n = 13) with an average duration (measured at half maximum amplitude) of 9.6 ? 2.1 set (range 5-12 set). Treatment with forskolin (l-10 pM, 10 min) increased these responses to 161 -t 10% of pretreatment controls (n = 13, p < O.OOOOOl), while the duration also increased to 121 ? 7% of controls (p < 0.01) (Fig. 3) . TTX is a blocker of voltage-activated sodium channels and, consequently, of synaptic transmission. Forskolin's enhancement occurred with TTX (1 pM, n = 8) in the bath and in the presence of the NMDA GluR antagonist AP-5 (10 FM, n = 4). The enhancement of AMPAIKA GluR-induced responses peaked between 24 + 3 min after end of the forskolin treatment and on average recovered 46 -+ 4 min from the start of the wash (Fig. 3B) . By these measures, the time course of forskolin's enhancement of AMPA/KA GluR-induced responses and EPSP amplitude were not significantly different.
Forskolin treatment also enhanced NMDA-induced responses (Fig. 4) . Under the conditions in which the present experiments were performed, the iontophoretic application of NMDA acts through NMDA GluRs; that is, NMDA-induced responses were blocked by AP-5 but not by CNQX or AP-3. NMDA application produced an average peak depolarization of 8.0 + 1 mV (range 3-14 mV, n = 12), with a duration of 18.5 2 3.2 set (range lo-43 set). Bath-applied forskolin (l-10 pM, 10 min) increased both the amplitude (peak depolarization 157 ? 10% of pretreatment controls, n = 12, p < 0.0001) and duration (half amplitude duration 156 + 12% of controls, p < 0.01) of the NMDAevoked responses. This enhancement occurred in the presence of TTX (1 FM, n = 6) and the AMPA/KA GluR antagonist CNQX (10 FM, n = 6). On average, the potentiation of the NMDA-induced response peaked 6 ? 1 min after the end of forskolin treatment and reversed by 24 ? 2 min (Fig. 4B) . By these measures, the time course of forskolin's enhancement of NMDA GluR-induced responses was significantly faster than forskolin's potentiation of EPSP amplitude (p < 0.01). In two neurons, it was possible to demonstrate that forskolin's enhancement of NMDA and AMPA/KA GluR-evoked responses occurred with different time courses in the same cell.
Discussion
The findings of this study demonstrate that cAMP/PKA-dependent mechanisms can actively regulate excitatory synaptic transmission in neostriatal brain slices. Activation of adenylate cy- Each trace is the average of four clase by forskolin enhanced the amplitude and duration of the EPSP evoked by local stimulation in neostriatal slices. This effect was mimicked by the PKA activator Sp-CAMPS and inhibited by the PKA inhibitors Rp-CAMPS and PKI. Furthermore, application of these PKA inhibitors alone depressed while the phosphatase inhibitor okadaic acid enhanced this evoked synaptic response. Finally, forskolin was found to enhance the responses of neostriatal neurons evoked by the application of AMPA/KA and NMDA GluR agonists. It is likely that forskolin's potentiation of synaptic transmission in the neostriatum is mediated by activation of adenylate cyclase. It is well established that 3H-forskolin binding sites (Gehlert et al., 1985; Worley et al., 1986; Poat et al., 1988; Stockmeier and Zhang, 1993) as well as adenylate cyclase mRNA (Matsuoka et al., 1992; Glatt and Snyder, 1993) are abundant in the neostriatum. Furthermore, forskolin has been shown to both stimulate CAMP levels and activate PKA in neostriatal cells and tissue (Daly et al., 1982; Battaglia et al., 1986; Seaman and Daly, 1986; Chneiweiss et al., 1991; Matsuoka et al., 1992) . In the present study, forskolin-induced potentiation occurred over a range of doses and with a time course consistent with a CAMP-dependent mechanism (Daly et al., 1982; Battaglia et al., 1986; Seaman and Daly, 1986; Matsuoka et al., 1992) . Finally, treatment with the inactive analog 1,9-dideoxyforskolin (Laurenza et al., 1989) did not alter the evoked EPSP If forskolin enhances synaptic transmission through PKA, then this enhancement should be blocked by inhibiting PKA activity and mimicked by stimulating PKA. Application of the competitive PKA inhibitor Rp-CAMPS attenuated both the amplitude and duration of forskolin's potentiation. Since Rp-c-AMPS can inhibit cyclic GMP-dependent kinase (PKG) as well as PKA (Hofmann et al., 1985) the effect of the intracellularly active PKA inhibitor PKI was also determined. PKI is a specific inhibitor of the catalytic subunit of PKA and has little or no t effect on other kinases including PKG (Cheng et al., 1986) . PKI alone inhibited EPSP amplitude and when forskolin was applied the EPSP amplitude was either unaffected or returned to original control levels. Evidence for the role of PKA was further strengthened by the finding that application of the PKA activator Sp-CAMPS mimicked the effects of forskolin in enhancing the EPSP amplitude. Thus, the results with the PKA agonist (Sp-CAMPS) and the PKA antagonists (Rp-CAMPS, PKI) demonstrate that PKA-dependent mechanisms regulate synaptic transmission in the neostriatum.
The observation that application of PKA inhibitors Rp-c-AMPS and PKI reduced the EPSP amplitude indicates that PKA is tonically active in regulating synaptic transmission in neostriatal neurons. In addition, a role for tonic phosphatase activity is suggested by the finding that the protein phosphatase inhibitor okadaic acid enhanced the EPSP amplitude. Together, these results suggest that the balance between tonic kinase and phosphatase activity regulates the amplitude of evoked synaptic responses in the neostriatum.
Interestingly, in cultured hippocampal neurons, inhibiting PKA activity reduces the AMPAIKA GluR-mediated responses while inhibiting phosphatase activity has the opposite effect Wang et al., 1991) . Since the neostriatal EPSP is primarily mediated by AMPA/KA GluRs, a PKA-dependent modulation of these receptors may explain the potentiation of synaptic-evoked responses.
In the present study, forskolin potentiated responses evoked by the iontophoretic application of AMPA/KA GluR agonists. This effect is likely to be mediated postsynaptically since responses were evoked under conditions in which synaptic transmission was blocked (bath-applied TTX). The magnitude and time course of forskolin's enhancement of AMPA/KA GluRevoked responses was similar to that of forskolin's potentiation of evoked EPSP (see Fig. 3 Time (min) Figure 3 . Forskolin enhances AMPAKA GluR-induced responses. A, Intracellularly recorded responses to iontophoretically applied glutamate (GLU, top truces) and quisqualate (QUIS, botrom truces) from two cells prior to and after forskolin treatment (10 pM, 10 min). Data collected in the presence of TTX (1 PM) and the NMDA GluR antagonist . In this and in Figure 4A , the clrrows indicate the onset and offset of iontophoretic treatments, and hyperpolarizing current pulses (0.4 nA, 50 msec duration, 0.5 Hz) were applied as a measure of membrane conductance. B, Time course of forskolin's (FKN, jilled rectangle) enhancement of AMPAKA GluR-mediated responses (0, n = 13). Long dashed line illustrates effects of forskolin on EPSP amplitude. that these receptors can be modulated by CAMP-dependent prolation of non-NMDA GluR-evoked responses is mediated via a cesses (see discussion below). In the neostriatum, a previous decrease in PKA activity. Certainly, the present results are constudy reported that the D2 receptor agonist quinpirole inhibited sistent with the hypothesis that cAMP/PKA-dependent mecharesponses evoked by AMPA/KA GluR agonists (Cepeda et al., nisms potentiate evoked EPSPs by altering the neostriatal cell's 1993). Since D2 receptor activation inhibits adenylate cyclase response to glutamate. and thus decreases PKA activity, it is possible that DA's reguForskolin also enhanced NMDA GluR-evoked responses. This enhancement is likely due to postsynaptic NMDA GluR activation since it occurred in the presence of 'ITX and CNQX. The time course of this potentiation was quite distinct from that of forskolin's regulation of either AMPAIKA GluR-evoked responses or evoked EPSPs (Fig. 4) . Evidence for cAMP/PKAdependent potentiation of NMDA-evoked response has also been found in cultured spinal cord neurons (Ceme et al., 1993) but not in other preparations Wang et al., 1991; Durand et al., 1992) . In the neostriatum, a recent study found that dopamine, acting through Dl receptors, potentiates NMDA-evoked responses (Cepeda et al., 1993) . The finding that forskolin produces a similar effect suggests that dopamine acts through a CAMP-dependent mechanism to regulate the NMDA receptor in neostriatal tissue.
Although CAMP and PKA could act either pre-or postsynaptically to enhance synaptic transmission, evidence indicates that postsynaptic mechanisms are involved. First, forskolin alters the responsiveness of neostriatal neurons to GluR agonists under (Knapp and Dowling, 1987; Linman et al., 1989; Knapp et al., 1990; Greengard et al., 1991; Mori-Okamota et al., 1991; Wang et al., 1991; Keller et al., 1992; Raymond et al., 1993b; Wang et al., 1993) . At least in expression systems, GluR6 is directly phosphorylated and preventing this phosphorylation eliminates PKA-mediated potentiation (Raymond et al., 1993; Wang et al., 1993) . However, not all GluR subunits appear to be directly phosphorylated by PKA (McGlade-McCulloh et al., 1993; Tan et al., 1994 ) and forskolin's potentiation of GluR-mediated responses in the neostriatum could be due to another mechanism.
One alternative is that PKA may phosphorylate a regulatory protein which in turn indirectly alters GluR-induced responses. For example, inhibitors of protein phosphatase activity (DARPP-32 and phosphatase inhibitor 1) have been found in neostriatal neurons (Nairn et al., 1988) . These regulatory proteins, when phosphorylated by PKA, will inhibit phosphatase 1 (Walaas et al., 1983; Hemmings et al., 1984; Williams et al., 1986) . The observation that application of the phosphatase inhibitor okadaic acid mimics the effects of cAMP/PKA activation on the evoked EPSP is at least consistent with this possibility.
Thus, PKA may modulate GluR-evoked responses either by directly phosphorylating the receptors or indirectly through regulation of phosphatase activity. A growing body of evidence suggests that regulation of synaptic communication through phosphorylation/dephosphorylation could be common (e.g., Nairn et al., 1985; Raymond et al., 1993a) . In the present study, the possibility that this regulation occurs in the neostriatum was examined by determining the effects of pharmacological manipulation of PKA and phosphatase activity on excitatory synaptic transmission. Among other results, treatments which increase protein phosphorylation (i.e., increase in kinase activity or decrease in phosphatase activity) enhanced synaptic-evoked responses, while treatments which decrease protein phosphorylation decreased these responses. At least some of this modulation can be explained by a postsynaptic regulation of the neostriatal neuron's response to GluR agonists. Limited evidence for CAMP-dependent modulation of excitatory synaptic transmission has been previously described (e.g., Cerne et al., 1992; Chavez-Noriega and Stevens, 1992) . These results suggest that the balance between kinase and phosphatase activity may play a general role in regulating synaptic transmission in 
